, Columnist
Alzheimer’s Bust Is Way Beyond a Setback for Biogen
Treating the disease was the focus of its future — and now investors are paying the price.
A big failure clouds a biotech giant’s future, and argues for changes.
Photographer: Scott Eisen/Bloomberg
This article is for subscribers only.
A train wreck that everyone sees coming still hurts.
Biogen Inc. announced Thursday that it was discontinuing late-stage studies of its Alzheimer’s medicine aducanumab. That shouldn’t be a huge surprise: Every other drug attempting to treat Alzheimer’s the same way — by targeting the buildup of amyloid beta plaques in the brain — has failed.